Abura, containing Abiraterone Acetate, is a medication used primarily in the treatment of prostate cancer. It works by inhibiting the production of androgens, which are hormones that can promote the growth of cancer cells in the prostate.
Abiraterone Acetate targets the enzyme CYP17, which is involved in the synthesis of androgens in the adrenal glands, testes, and prostate tumor tissue. By blocking this enzyme, Abura reduces the levels of testosterone and other male hormones, helping to slow the growth of cancer cells.
Abura is indicated for use in combination with prednisone for patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy. It is also recommended for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) when used in conjunction with androgen deprivation therapy.
The recommended dosage of Abura is typically taken once daily, on an empty stomach. Patients should follow their healthcare provider's instructions regarding the exact dosage and timing.
Common side effects may include fatigue, joint pain, hot flashes, and increased blood pressure. Serious side effects can occur, so it's essential for patients to report any unusual symptoms to their healthcare provider promptly.
Patients should inform their doctor of any existing medical conditions, especially liver issues, as dose adjustments may be necessary. Regular monitoring of liver function and blood pressure is recommended during treatment.
Abura may interact with certain medications, including corticosteroids and anti-seizure drugs. It’s crucial to discuss all medications and supplements with a healthcare provider before starting Abura to avoid potential interactions.
Abura (Abiraterone Acetate) offers a targeted approach to managing prostate cancer by effectively reducing androgen levels. Patients should work closely with their healthcare team to ensure safe and effective treatment.